A Subcutaneous Octreotide Hydrogel Implant for the Treatment of Acromegaly

Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study

Annamaria Colao, Renata S. Auriemma, Mariano Galdiero et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 151 citations · Full text

Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles

B Astruc, Peter Marbach, Hakim Bouterfa et al. · The Journal of Clinical Pharmacology · 2005 · 121 citations

Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTa

Jean Christophe Maiza, Delphine Vezzosi, Maria Matta et al. · Clinical Endocrinology · 2007 · 117 citations · Full text

Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial

Erica A. Eugster, William L. Clarke, Gad B. Kletter et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 116 citations

Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institution

Raquel S. Jallad, Nina Rosa de Castro Musolino, L R Salgado et al. · Clinical Endocrinology · 2005 · 87 citations